Turnstone Biologics is a clinical-stage biotech company focused on developing innovative cancer immunotherapies, particularly through its pioneering Selected TIL (tumor-infiltrating lymphocyte) therapies. The company aims to address the significant challenges in treating solid tumors by selecting and expanding the most potent tumor-reactive T cells, which enhances the efficacy of immunotherapy. Their lead program, TIDAL-01, is currently in Phase 1 trials, and they are also exploring viral immunotherapy combinations to further improve treatment outcomes. With a strong management team and strategic partnerships, Turnstone is positioned to make a significant impact in the oncology market.
Something looks off?